

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Davis Andrew S.</u>			2. Issuer Name and Ticker or Trading Symbol <u>Silk Road Medical Inc [ SILK ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <u>Chief Commercial Officer</u>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>05/01/2023</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
C/O SILK ROAD MEDICAL, INC. 1213 INNSBRUCK DRIVE			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street)	CA	94089	Rule 10b5-1(c) Transaction Indication					
(City)	(State)	(Zip)	<input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.					

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/01/2023		M <sup>(1)</sup>		482	A	\$6.11	116,165	D	
Common Stock	05/01/2023		M <sup>(1)</sup>		474	A	\$20	116,639	D	
Common Stock	05/01/2023		M <sup>(1)</sup>		2,584	A	\$4.73	119,223	D	
Common Stock	05/01/2023		M <sup>(1)</sup>		3,213	A	\$4.73	122,436	D	
Common Stock	05/01/2023		S <sup>(1)</sup>		482	D	\$44.5125 <sup>(2)</sup>	121,954	D	
Common Stock	05/01/2023		S <sup>(1)</sup>		474	D	\$44.5125 <sup>(2)</sup>	121,480	D	
Common Stock	05/01/2023		S <sup>(1)</sup>		2,584	D	\$44.5125 <sup>(2)</sup>	118,896	D	
Common Stock	05/01/2023		S <sup>(1)</sup>		3,213	D	\$44.5125 <sup>(2)</sup>	115,683	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Option (right to buy)	\$4.73	05/01/2023		M <sup>(1)</sup>			3,213	09/01/2017 <sup>(3)</sup>	11/30/2027	Common Stock	3,213	\$0	44,238	D	
Option (right to buy)	\$6.11	05/01/2023		M <sup>(1)</sup>			482	08/01/2019 <sup>(3)</sup>	09/13/2028	Common Stock	482	\$0	1,853	D	
Option (right to buy)	\$20	05/01/2023		M <sup>(1)</sup>			474	05/03/2019 <sup>(3)</sup>	04/03/2029	Common Stock	474	\$0	33,220	D	
Option (right to buy)	\$4.73	05/01/2023		M <sup>(1)</sup>			2,584	04/04/2021 <sup>(3)</sup>	11/30/2027	Common Stock	2,584	\$0	18,720	D	

**Explanation of Responses:**

- The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on May 20, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
- This transaction was executed in multiple trades at price ranging from \$43.99 to \$45.02. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- All of the shares subject to the option are fully vested and exercisable as of the date hereof.

**Remarks:**

/s/Mhairi Jones, by power of attorney 05/01/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**